Kimberly Blackwell Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading activity

Kimberly Blackwell is Chief Executive Officer of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 484,145 shares of ZNTL, which is worth approximately $1.56 Million. The most recent transaction as insider was on Feb 01, 2024, when has been sold 20,655 shares (Common Stock) at a price of $11.69 per share, resulting in proceeds of $241,456. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 484K

0% 3M change

93.81% 12M change

Total Value Held $1.56 Million

Kimberly Blackwell Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 01 2024	SELL Payment of exercise price or tax liability	$241,456 $11.69 p/Share	20,655 Reduced 4.09%	484,145 Common Stock
Feb 01 2024	BUY Grant, award, or other acquisition	-	250,000 Added 33.12%	504,800 Common Stock
Nov 13 2023	BUY Open market or private purchase	$51,449 $10.29 p/Share	5,000 Added 1.92%	254,800 Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	244,800 Added 49.49%	249,800 Common Stock
Jan 03 2022	SELL Open market or private sale	$83,740 $83.74 p/Share	1,000 Reduced 16.67%	5,000 Common Stock
Jan 03 2022	BUY Exercise of conversion of derivative security	$47,800 $47.8 p/Share	1,000 Added 14.29%	6,000 Common Stock
Dec 01 2021	SELL Open market or private sale	$81,840 $81.84 p/Share	1,000 Reduced 16.67%	5,000 Common Stock
Dec 01 2021	BUY Exercise of conversion of derivative security	$47,800 $47.8 p/Share	1,000 Added 14.29%	6,000 Common Stock
Nov 01 2021	SELL Open market or private sale	$80,460 $80.46 p/Share	1,000 Reduced 16.67%	5,000 Common Stock
Nov 01 2021	BUY Exercise of conversion of derivative security	$47,800 $47.8 p/Share	1,000 Added 14.29%	6,000 Common Stock
Oct 25 2021	SELL Open market or private sale	$77,590 $77.59 p/Share	1,000 Reduced 16.67%	5,000 Common Stock
Oct 25 2021	BUY Exercise of conversion of derivative security	$47,800 $47.8 p/Share	1,000 Added 14.29%	6,000 Common Stock
Jun 04 2021	BUY Grant, award, or other acquisition	-	5,000 Added 50.0%	5,000 Common Stock

Also insider at

IPSC

Century Therapeutics, Inc. Healthcare

Director

GLUE

Monte Rosa Therapeutics, Inc. Healthcare